Wire · opportunities
AstraZeneca partners with AI biotech insitro on liver, heart drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 October 2026 · Fusion42 review
AstraZeneca has entered a multi-year drug discovery collaboration with AI biotech insitro, valued up to $1.5 billion, to develop treatments for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will use its Virtual Human AI platform to identify drug targets, while AstraZeneca will handle clinical development and regulatory pathways.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 15 Oct 2026 and 16 Oct 2026.
◆ ◆ The Wire takeaway
Your drug discovery process just shifted as AstraZeneca proved AI can guide complex disease target selection beyond traditional research delays. Focus on generating actionable biological data early to compete in the cardiometabolic and liver disease space.
◆ Coverage
1 source · first reported 15 Oct 2026 · latest 16 Oct 2026
◆ Related on Wire
◆ Topics